PDF icon Download PDF
Open Access
CC BY 4.0 · Arq Neuropsiquiatr 2025; 83(08): s00451811235
DOI: 10.1055/s-0045-1811235
Review Article

Which are the options and dosages for clobazam shortages on epilepsy treatment? Review of literature and survey of specialists

Lécio Figueira Pinto 
1   Universidade de São Paulo, Faculdade de Medicina, São Paulo SP, Brazil.
,
Guilherme Simone Mendonça 
2   Hospital Santa Isabel, Blumenau SC, Brazil.
,
Carlos Alberto Mantovani Guerreiro 
3   Universidade Estadual de Campinas, Faculdade de Ciências Médicas, Campinas SP, Brazil.
› Author Affiliations
› Further Information
Also available ateRef
  Permissions and Reprints
Preview

Abstract

Clobazam (CLB) has been an established treatment for epilepsy since the 1970s, with a broad spectrum. It is frequently used as add on therapy for refractory patients. Furthermore, it is different from classic benzodiazepines (BZD) for containing nitrogen atoms in 1 and 5 positions of B ring (other are 1.4-BZD). This explains why CLB has a better tolerability and a lower chance of causing sedation, being an excellent option for epilepsy treatment compared with other BZDs. Evidence argues against the development of CLB tolerance in most patients. Antiseizure medication shortages have been reported by many countries, including the one studied here. Shortages make treatment harder, increase the need for extra clinical appointments, for orientation and medication changes, increase medication errors, decrease adherence, and cause insecurity. A literature review showed scarce evidence of alternatives, with a wide variation in dosage equivalence. A survey of specialists revealed that switch appropriateness was deemed inadequate by the majority, due to risk of seizure worsening and side effects. Clonazepam and nitrazepam were the most used BZDs, but there was great variation for clonazepam dosages (0.25–2 mg, commonly 1 per 10 mg of CLB). Better consensus was obtained for nitrazepam (5 per 10 mg of CLB). Gradual tapering of CLB, with concomitant increase of clonazepam or nitrazepam under close supervision, is advised. It is important to assess tolerability and the need for increased dosage. As CLB is an essential tool in the epilepsy armamentarium, shortages pose great risk to the patients. Governments and society must create mechanisms to prevent shortages of critical and unique medications.

Keywords

Clobazam - Epilepsy - Dosage - Surveys and Questionnaire - Review

Authors' Contributions

Conceptualization: LFP, GM; data curation: LFP, GM; formal analysis: LFP, GM, CAG; investigation: LFP; methodology: LFP, GM, CAG; project administration: LFP.


Data Availability Statement

The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.


Editor-in-Chief: Hélio A. G. Teive. ORCID is 0000-0003-2305-1073.


Associate Editor: Luciano De Paola. ORCID is 0000-0002-0512-610X.




Publication History

Received: 10 April 2025

Accepted: 10 June 2025

Article published online:
08 September 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

Bibliographical Record
Lécio Figueira Pinto, Guilherme Simone Mendonça, Carlos Alberto Mantovani Guerreiro. Which are the options and dosages for clobazam shortages on epilepsy treatment? Review of literature and survey of specialists. Arq Neuropsiquiatr 2025; 83: s00451811235.
DOI: 10.1055/s-0045-1811235